IP Library Granted Patent US 10,064,853
Granted Patent B2
US 10,064,853 · App. 15/632,809 · Granted Sep 4, 2018

Compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase

Inventors: Robert Flaumenhaft (Newton, MA); Partha Pratim Nag (Somerville, MA); Tatiana Pilyugina (Waltham, MA); Jun Pu (Shrewsbury, MA); Sivaraman Dandapani (Malden, MA); Benito Munoz (Newtonville, MA); Chris Dockendorff (Arlington, MA)
Assignees: Beth Israel Deaconess Medical Center, Inc.; The Broad Institute, Inc.
A61K31/445A61K31/454
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,064,853
App. No.
15/632,809
Granted
Sep 4, 2018
Kind
B2
Abstract

The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I)

Claims (36)

1. A method for treating acute myocardial infarction, transient ischemic attacks, peripheral vascular disease, pulmonary embolism, or deep vein thrombosis in a patient, comprising administering to the patient a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or solvent, wherein:

R 1 is OH or acyloxy;

R 2 is selected from H, lower alkyl, and halogen;

R 3 and R 4 are independently selected from H, F, and alkyl, or R 3 and R 4 taken together with the carbon atom to which they are attached form a carbonyl group or a substituted or unsubstituted 3-7 membered cycloalkyl ring;

R 5 is OR 7 , or NR 7 R 8 , wherein R 7 and R 8 are each independently selected from H and substituted or unsubstituted alkyl, aryl, aralkyl, cycloalkyl, and cycloalkylalkyl, or taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted 3-7 membered heterocyclyl ring;

W represents a C 1 -C 3 alkylene group;

X is selected from O, S, and NR 9 , wherein R 9 is H or lower alkyl; and

R 6 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

2. The method according to claim 1 , wherein R 1 is OH.

3. The method according to claim 1 , wherein R 2 is H or Cl.

4. The method according to claim 1 , wherein R 3 and R 4 are H, or R 3 and R 4 taken together with the carbon atom to which they are attached form a carbonyl group.

5. The method according to claim 1 , wherein R 5 is OR 7 , wherein R 7 is substituted or unsubstituted alkyl.

6. The method according to claim 1 , wherein W is ethylene.

7. The method according to claim 1 , wherein X is O.

8. The method according to claim 1 , wherein R 6 is substituted or unsubstituted aryl.

9. The method according to claim 1 , wherein the compound is a compound having a structure selected from:

or a pharmaceutically acceptable salt thereof.

10. A method for inhibiting protein disulfide isomerase in a cell, comprising contacting the cell with a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or solvent, wherein:

R 1 is OH or acyloxy;

R 2 is selected from H, lower alkyl, and halogen;

R 3 and R 4 are independently selected from H, F, and alkyl, or R 3 and R 4 taken together with the carbon atom to which they are attached form a carbonyl group or a substituted or unsubstituted 3-7 membered cycloalkyl ring;

R 5 is OR 7 , or NR 7 R 8 , wherein R 7 and R 8 are each independently selected from H and substituted or unsubstituted alkyl, aryl, aralkyl, cycloalkyl, and cycloalkylalkyl, or taken together with the nitrogen atom to which they are attached form a substituted or unsubstituted 3-7 membered heterocyclyl ring;

W represents a C 1 -C 3 alkylene group;

X is selected from O, S, and NR 9 , wherein R 9 is selected from H or lower alkyl; and

R 6 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.

11. The method according to claim 10 , wherein R 1 is OH.

12. The method according to claim 10 , wherein R 2 is H or Cl.

13. The method according to claim 10 , wherein R 3 and R 4 are H, or R 3 and R 4 taken together with the carbon atom to which they are attached form a carbonyl group.

14. The method according to claim 10 , wherein R 5 is OR 7 , wherein R 7 is substituted or unsubstituted alkyl.

15. The method according to claim 10 , wherein W is ethylene.

16. The method according to claim 10 , wherein X is O.

17. The method according to claim 10 , wherein R 6 is substituted or unsubstituted aryl.

18. The method according to claim 10 , wherein the compound is a compound having a structure selected from:

or a pharmaceutically acceptable salt thereof.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2018
From: NAG, PARTHA PRATIM; PILYUGINA, TATIANA; PU, JUN; DANDAPANI, SIVARAMAN; MUNOZ, BENITO; DOCKENDORFF, CHRIS
To: THE BROAD INSTITUTE, INC.
Reel/Frame 045882/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2018
From: FLAUMENHAFT, ROBERT
To: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Reel/Frame 045744/0455 →
CONFIRMATORY LICENSE Recorded Apr 2, 2018
From: BETH ISRAEL DEACONESS MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045804/0565 →
Continuity (3)
Division 14899180
Provisional Application 61837820 · Jun 21, 2013
Related Publication 20170304283A1 · Oct 26, 2017